臨床検査50巻1号

2006年01月発行

今月の主題 PK/PD解析を指標とした感染症治療 総説

抗菌薬治療における副現象とPK/PD―1．耐性菌の出現

著者： 満山順一¹

所属機関： ¹富山化学工業株式会社綜合研究所第三研究部

ページ範囲：P.23 - P.31

薬剤耐性菌は感染症治療における大きな問題のひとつである．耐性菌の出現を抑制するための研究は遅れていたが，近年，その出現を完全に抑制する濃度（Mutant prevention concentration；MPC）と選択濃度域（Mutant selection window；MSW）の考え方が見出され，pharmacokinetics/pharmacodynamics（PK/PD）の概念と組み合わせることにより，耐性菌の出現を理論的に解析しようとする試みがなされている．〔臨床検査　50：23-31，2006〕

参考文献

1） Li XZ：Quinolone resistance in bacteria；emphasis on plasmid-mediated mechanisms. Int J Antimicrob Agents 25：453-463, 2005

２） Munshi MH, Sack DA, Haider K, et al：Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet　22：419-421, 1987

３） Van Bambeke F, Tulkens PM：Macrolides：pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents　18：S17-23, 2001

４） Craig WA：Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am　17：479-501, 2003

５） Nicolau DP：Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother　9：292-296, 2003

６） Dong Y, Zhao X, Domagala J, et al：Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother　43：1756-1758, 1999

７） Lu T, Zhao X, Li X, et al：Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother　52：61-64, 2003

８） Zhao X, Eisner W, Perl-Rosenthal N, et al：Mutant prevention concentration of garenoxacin （BMS-284756） for ciprofloxacin-susceptible or-resistant Staphylococcus aureus. Antimicrob Agents Chemother　47：1023-1027, 2003

９） Li X, Zhao X, Drlica K：Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother　46：522-524, 2002

10） Blondeau JM, Zhao X, Hansen G, et al：Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother　45：433-438, 2001

11） Hansen GT, Metzler K, Drlica K, et al：Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother　47：440-441, 2003

12） Zhao X, Drlica K：Restricting the selection of antibiotic-resistant mutant bacteria；measurement and potential use of the mutant selection window. J Infect Dis　185：561-565, 2002

13） Randall LP, Cooles SW, Piddock LJ, et al：Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. J Antimicrob Chemother　54：688-691, 2004

14） Dong Y, Zhao X, Kreiswirth BN, et al：Mutant prevention concentration as a measure of antibiotic potency：studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother　44：2581-2584, 2000

15） Sindelar G, Zhao X, Liew A, et al：Mutant prevention concentration as a measure of fluoroquinolone potency against Mycobacteria. Antimicrob Agents Chemother　44：3337-3343, 2000

16） Firsov AA, Vostrov SN, Lubenko IY, et al：In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother　47：1604-1613, 2003

17） Firsov AA, Vostrov SN, Lubenko IY, et al：Concentration-dependent changes in susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents　23：60-66, 2004

18） Allen GP, Kaatz GW, Rybak MJ：In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents　24：150-160, 2004

19） Campion JJ, McNamara PJ, Evans ME：Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother　48：4733-4744, 2004

20） Campion JJ, Chung P, McNamara PJ, et al：Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother　49：2189-2199, 2005

21） Zinner SH, Lubenko IY, Gilbert D, et al：Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window；related change in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother　52：616-622, 2003

22） Allen GP, Kaatz GW, Rybak MJ：Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chmother　47：2606-2614, 2003

23） Ebisu H, Kishii R, Takei M, et al：The effect of pharmacokinetic / pharmacodynamic （PK/PD） parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae. J Infect Chemother　9：210-214, 2003

24） Croisier D, Etienne M, Bergoin E, et al：Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabit model of human thrapy. Antimicrob Agents Chemother　48：1699-1707, 2004

25） MacGowan AP, Rogers CA, Holt HA, et al：Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother　47：1088-1095, 2003

26） Croisier D, Etienne M, Piroth L, et al：In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia；impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother　54：640-647, 2004

27） Smith J, Nichol KA, Hoban DJ, et al：Stretching the mutant prevention concentration （MPC） beyond its limits. J Antimicrob Chemother　51：1323-1325, 2003

28） 大西由美，満山順一，山口惠三：In vitro pharmacokinetic modelを用いたS.arueusのキノロン耐性化に関する検討（第三報）．第52回日本化学療法学会総会（沖縄）：一般演題65，2004

29） 福田淑子，高畑正裕，満山順一：In vitro pharmacokinetic modelを用いたキノロン系抗菌薬の肺炎球菌に対する殺菌作用及び耐性菌出現に関する検討．第52回日本化学療法学会西日本支部総会（神戸）：一般演題06，2004